BidaskClub downgraded shares of Dermira, Inc. (NASDAQ:DERM) from a hold rating to a sell rating in a research report released on Wednesday.

Several other analysts have also commented on the company. Mizuho dropped their target price on Dermira from $42.00 to $40.00 and set a buy rating on the stock in a report on Thursday, May 25th. Evercore ISI initiated coverage on Dermira in a report on Thursday, June 29th. They set an outperform rating and a $48.00 target price on the stock. Cantor Fitzgerald initiated coverage on Dermira in a report on Thursday, June 22nd. They set an overweight rating and a $45.00 target price on the stock. Needham & Company LLC reaffirmed a buy rating and set a $46.00 target price on shares of Dermira in a report on Tuesday, July 18th. Finally, Zacks Investment Research lowered Dermira from a hold rating to a sell rating in a report on Friday, July 28th. Five investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and an average price target of $43.80.

Dermira (NASDAQ:DERM) opened at 26.44 on Wednesday. Dermira has a 52 week low of $25.63 and a 52 week high of $38.75. The company’s 50 day moving average price is $29.16 and its 200-day moving average price is $30.96. The company’s market capitalization is $1.10 billion.

WARNING: “Dermira, Inc. (NASDAQ:DERM) Cut to “Sell” at BidaskClub” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/08/06/dermira-inc-nasdaqderm-cut-to-sell-at-bidaskclub.html.

In other Dermira news, CEO Thomas G. Wiggans sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $27.52, for a total value of $137,600.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Christopher M. Griffith sold 1,312 shares of the firm’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $27.07, for a total value of $35,515.84. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,812 shares of company stock worth $482,231. 13.30% of the stock is owned by corporate insiders.

Hedge funds have recently modified their holdings of the stock. BNP Paribas Arbitrage SA raised its stake in shares of Dermira by 2,220.7% in the second quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 3,975 shares during the last quarter. SG Americas Securities LLC increased its position in Dermira by 66.8% in the second quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 2,203 shares during the period. KCG Holdings Inc. purchased a new position in Dermira during the first quarter valued at $215,000. Legal & General Group Plc increased its position in Dermira by 16.3% in the first quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 963 shares during the period. Finally, Tocqueville Asset Management L.P. purchased a new position in Dermira during the first quarter valued at $256,000. 84.54% of the stock is currently owned by institutional investors.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.